FDA is moving toward easing restrictions on certain compounded peptides after signaling it will convene outside advisers to reassess whether some U.S. pharmacies should be allowed to manufacture peptides previously restricted over safety concerns. The planned reviews come after HHS Secretary Robert F. Kennedy Jr. publicly backed allowing compounding of 14 peptides, following scrutiny of compounds including BPC-157, TB-500, and KPV. The FDA’s prior restrictions targeted peptides produced by compounding pharmacies, not standard drug manufacturing, and were tied to “significant safety risks.” The new advisory-panel process is expected to be staged, with one meeting slated for July and additional review later. For biotech stakeholders, the procedural shift raises practical questions for the regulated supply chain: how the FDA defines acceptable manufacturing controls and labeling when the same peptide classes were previously flagged. It also increases the chance that demand for certain non-approved peptides could surge if compounding is expanded.